All In Biotech

NDA 210951 · Janssen Biotech

Erleada

Apalutamide · Oral

NovelPriority review

Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Feb 14, 2018

Approved uses

5

Original approval plus efficacy supplements

Registered trials

138

30 Phase 3, 39 recruiting

FAERS reports

12,037

7,475 serious, 1,541 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jul 2, 2026.

ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC) ERLEADA is an androgen receptor inhibitor indicated for the treatment of patients with metastatic castration-sensitive prostate cancer. ( 1 ) non-metastatic castration-resistant prostate cancer. ( 1 )

Mechanism: Apalutamide is an Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR. Apalutamide inhibits AR nuclear translocation, inhibits DNA binding, and impedes AR-mediated transcription. A major metabolite, N-desmethyl apalutamide, is a less potent inhibitor of AR, and exhibited one-third the activity of apalutamide in an in vitro transcriptional reporter assay. Apalutamide administration caused decreased tumor cell proliferation and increased apoptosis leading to decreased tumor volume in mouse xenograft models of prostate cancer.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 19, 2023 Supplement 14 · Efficacy LetterLabel
  • Sep 7, 2021 Supplement 6 · Efficacy LetterLabel
  • Nov 20, 2020 Supplement 4 · Efficacy · priority review LabelLetter
  • Sep 17, 2019 Supplement 1 · Efficacy · priority review LabelLetter
  • Feb 14, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelLabelLetterReview
2 products under this application
  • ERLEADA · APALUTAMIDE 60MG · TABLET, ORAL · Prescription · TE AB
  • ERLEADA · APALUTAMIDE 240MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Apalutamide" as an intervention, any sponsor and status, largest first.

All 138 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • rash1,336
  • fatigue1,240
  • death1,203
  • hot flush922
  • product dose omission issue450
  • asthenia443
  • diarrhoea421
  • dizziness376
  • arthralgia371
  • off label use365
  • fall354
  • decreased appetite330

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
20164
20175
2018363
2019838
20201,248
20211,023
20222,105
20231,761
20241,837
20251,811
20261,041

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Erleada (Apalutamide)

2024 spending

$1.39B

Beneficiaries

13,253

95,580 claims

Per beneficiary

$104,603

$233.33 per unit

View as table
YearSpending
2020$469,314,125
2021$734,682,218
2022$877,671,428
2023$1,057,789,083
2024$1,386,301,873

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 191 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.